Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMYTNASDAQ:HCMNASDAQ:INDV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMYTAmryt Pharma$14.70+0.1%$14.64$6.41▼$14.77$940.21M0.84757,360 shs2.39 million shsHCMHUTCHMED$14.85-2.0%$14.93$11.51▼$21.92$2.59B0.66105,124 shs33,424 shsINDVIndivior$11.51-2.0%$9.61$7.33▼$18.59$1.62B0.93976,951 shs748,537 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMYTAmryt Pharma0.00%0.00%0.00%0.00%0.00%HCMHUTCHMED-2.04%-2.30%-1.26%+7.53%-19.77%INDVIndivior-2.04%+21.99%+20.78%-5.66%-34.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMYTAmryt PharmaN/AN/AN/AN/AN/AN/AN/AN/AHCMHUTCHMED1.9431 of 5 stars3.02.00.00.02.00.01.9INDVIndivior3.3529 of 5 stars3.63.00.00.02.71.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMYTAmryt Pharma 0.00N/AN/AN/AHCMHUTCHMED 2.00Hold$19.0027.95% UpsideINDVIndivior 3.25Buy$15.0030.32% UpsideCurrent Analyst Ratings BreakdownLatest HIK, HCM, INDV, and AMYT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMYTAmryt Pharma$222.54M4.22$0.98 per share14.98$5.58 per share2.63HCMHUTCHMED$630.20M4.11$0.61 per share24.51$4.27 per share3.48INDVIndivior$1.17B1.36$2.33 per share4.94N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMYTAmryt Pharma$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/AHCMHUTCHMED$100.78MN/A0.0010.17N/AN/AN/AN/A5/9/2025 (Estimated)INDVIndivior$2M-$0.31N/A6.73N/A-3.96%-241.73%15.09%N/ALatest HIK, HCM, INDV, and AMYT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million2/20/2025Q4 2024INDVIndivior$0.32$0.32N/A$0.07$262.35 million$298.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMYTAmryt PharmaN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMYTAmryt Pharma0.641.570.94HCMHUTCHMED0.072.812.68INDVIndiviorN/A0.830.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMYTAmryt Pharma71.31%HCMHUTCHMED8.82%INDVIndivior60.33%Insider OwnershipCompanyInsider OwnershipAMYTAmryt Pharma5.66%HCMHUTCHMED3.60%INDVIndiviorN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMYTAmryt Pharma2,02063.96 million60.34 millionNot OptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableINDVIndivior1,164137.88 millionN/ANot OptionableHIK, HCM, INDV, and AMYT HeadlinesRecent News About These CompaniesJPMorgan Chase & Co. Sells 376,955 Shares of Indivior PLC (NASDAQ:INDV)April 30 at 3:03 AM | marketbeat.comMelqart Asset Management UK Ltd Grows Position in Indivior PLC (NASDAQ:INDV)April 29 at 7:01 AM | marketbeat.comBoothbay Fund Management LLC Raises Stock Holdings in Indivior PLC (NASDAQ:INDV)April 29 at 6:24 AM | marketbeat.comFY2025 EPS Estimates for Indivior Lifted by Northland CapmkApril 29 at 2:25 AM | americanbankingnews.comFY2025 EPS Estimates for Indivior Boosted by Northland CapmkApril 29 at 2:23 AM | marketbeat.comIndivior PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsApril 28 at 12:58 PM | finance.yahoo.comIndivior: Trying To Break AddictionApril 28 at 12:58 PM | seekingalpha.comXTX Topco Ltd Sells 110,663 Shares of Indivior PLC (NASDAQ:INDV)April 28 at 3:58 AM | marketbeat.comWhat is Northland Capmk's Forecast for Indivior Q3 Earnings?April 27, 2025 | marketbeat.comIndivior (NASDAQ:INDV) Stock Price Up 5.6% on Earnings BeatApril 27, 2025 | americanbankingnews.comIndivior PLC (NASDAQ:INDV) Shares Purchased by Marshall Wace LLPApril 26, 2025 | marketbeat.comQ3 Earnings Forecast for Indivior Issued By Northland CapmkApril 26, 2025 | americanbankingnews.comIndivior (NASDAQ:INDV) Shares Gap Up Following Strong EarningsApril 26, 2025 | americanbankingnews.comBarclays PLC Trims Stock Position in Indivior PLC (NASDAQ:INDV)April 25, 2025 | marketbeat.comIndivior backs FY25 revenue view $955M-$1.03B, consensus $1.02BApril 24, 2025 | markets.businessinsider.comIndivior (INDV) Q1 2025 Earnings CallApril 24, 2025 | msn.comIndivior PLC (INDV) Q1 Earnings and Revenues Beat EstimatesApril 24, 2025 | zacks.comSIH Partners LLLP Invests $2.70 Million in Indivior PLC (NASDAQ:INDV)April 24, 2025 | marketbeat.comClaret Asset Management Corp Acquires New Position in Indivior PLC (NASDAQ:INDV)April 21, 2025 | marketbeat.comShort Interest in Indivior PLC (NASDAQ:INDV) Declines By 20.9%April 21, 2025 | americanbankingnews.comIndivior PLC (NASDAQ:INDV) Short Interest Down 20.9% in MarchApril 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHIK, HCM, INDV, and AMYT Company DescriptionsAmryt Pharma NASDAQ:AMYTAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.HUTCHMED NASDAQ:HCM$14.85 -0.31 (-2.04%) As of 04/30/2025 04:00 PM EasternHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Indivior NASDAQ:INDV$11.51 -0.24 (-2.04%) As of 04/30/2025 04:00 PM EasternIndivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
